Navigation Links
Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
Date:9/19/2013

tinues," "commitment," "providing support," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for Novartis Ph+ CML products or regarding potential future revenues from such products. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with a Novartis Ph+ CML product to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any Novartis Ph+ CML product will be approved for any additional indications or labeling in any market. Nor can there be any guarantee that any Novartis Ph+ CML product will achieve any particular levels of revenue in the future. In particular, management's expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the infor
'/>"/>
SOURCE Novartis
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
2. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
3. Leaders from Pfizer, Novartis and J&J Challenge Industry to Disrupt R&D
4. Novartis launches the Cancer Cell Line Encyclopedia to catalog worlds cancer cell lines
5. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
6. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
7. Spanish researchers writing in cell describe the 9 hallmarks of aging
8. Discovery of gene mutation causing Sturge-Weber syndrome, port-wine stain birthmarks offers new hope
9. Nutra Pharma Patent and Trademarks Published in India
10. Spider Bully for Less: My Cleaning Products Marks Down the Spray for its Christmas Special
11. My Cleaning Products Marks Down Its Bed Bug Bully Price by 20%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Physicians ... its cardiovascular pharmacogenetics menu, which enables healthcare providers ... With PCLS’s evidence-based results, healthcare providers are ... optimize their therapy, while minimizing risks for adverse ... U.S., according to the FDA [1] more than ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... the University of Illinois helped lead a collaborative ... for serious Staphylococcus aureus (Staph) infections. The research, ... of Science magazine, comes at a time when ... methicillin-resistant S. aureus) are spreading in epidemic proportions ...
... Pipeline ... Continues to Mature, SOUTH SAN FRANCISCO, Calif., Feb. 14 ... full,year and fourth quarter ended December 31, 2007., Revenues for the ... revenues for the full year was primarily due to,revenue recognition associated with ...
... IRVINE, Calif., Feb. 14 SectorWatch.biz announces the,availability ... the news and,driving markets today., Investors can ... by,visiting: http://www.SectorWatch.biz -- Click on MarketStats, ... include:,CardioVascular Bio Therapeutics, Inc. (OTC Bulletin Board: CVBT), ...
Cached Biology Technology:New approach may render disease-causing staph harmless 2New approach may render disease-causing staph harmless 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... the University of Copenhagen have shown for the first ... of Cystic fibrosis patients, giving them the opportunity to ... chronic infections. , The study also discovered the bacterial ... patients was halted or slowed down by the immune ... the oxygen and helped "suffocate" the bacteria, forcing the ...
(Date:10/16/2014)... Researchers at William and Mary,s Virginia Institute of ... from the Environmental Protection Agency to identify the ... and to develop tools to help local governments ... project depends critically on a dataset of tidal-marsh ... 1970s. Only with this historical baseline can today,s ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... with research associate Jerilyn Walker and assistant professor Miriam Konkel, ... ancient jumping genes called Alu, which are more than 16 ... the Zoological Society of San Diego and the Institute of ... open access journal Mobile DNA . These tiny ...
... are being investigated as a way of improving drug response ... launched today (Monday). Scientists at the Cancer Research UK ... (ECMC) in Leicester will investigate whether tablets containing curcumin ... to the standard treatment for bowel cancer that has spread. ...
... is available in German . Halle/Saale. In ... special strategies. These differ in part considerably from the propagation ... Dr. Sonja Knapp of the Helmholtz Centre for Environmental Research ... current issue of the scientific journal Ecology Letters . ...
Cached Biology News:LSU research finds orangutans host ancient jumping genes 2Trial launched into curry chemical's cancer-fighting properties 2Different recipes for success in the world of plants 2Different recipes for success in the world of plants 3
MOUSE ANTI HUMAN NPM...
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
... et.al. (1997) • Contains short ... biochemistry & molecular biology, arranged ... Entries give details of biochemical ... which they are involved and ...
Biology Products: